Overview
Epigenetic Regulation of Cancer in Response to Chemotherapy, Volume 158 of the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting chapters on timely topics, including Epigenetically Programmed Resistance to Chemotherapy and Promotion of Immune Evasion in Cancer, A Role for the Epigenome in Cancer Cell Drug Tolerance, Histone Methylation and X Chromosomal Genes in Metastasis of Breast Cancer, Targeting Epigenetic Regulation Using Small Molecule Inhibitors, Histone Deacetylase Inhibitors as Sanguine Epigenetic Therapeutics against Pugnacious Lung Cancer, From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia), and more. Additional chapters cover Predictive Models of Chemoresistance Generated by Crunching the Public Drug Screen, Epigenomic and Genomic Profiling Datasets via Regression-, Machine Learning, and Knowledge-Based Methods, Probing on the Mechanisms of lncRNAs on Cancer Drug Resistance, Drug Tolerant Persister Cells in Cancer: Current Knowledge and Therapeutic Perspectives, and much more.
Full Product Details
Author: Joseph Landry (Institute of Molecular Medicine, Virginia Commonwealth University, VA, USA) ,
Swadesh Das (Massey Cancer Center, Richmond, VA, USA) ,
Paul B. Fisher (Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USA)
Publisher: Elsevier Science Publishing Co Inc
Imprint: Academic Press Inc
Weight: 0.840kg
ISBN: 9780443194184
ISBN 10: 0443194181
Pages: 438
Publication Date: 27 March 2023
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: Manufactured on demand
We will order this item for you from a manufactured on demand supplier.
Author Information
Joseph Landry works at Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA. Dr. Swadesh Das works at Massey Cancer Center, Richmond, Virginia, USA. Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
